Phaseline

Companies › ARTBIO

ARTBIO: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Nov 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AB001
Pb-212 PSMA-targeted alpha-emitting radioligand
PSMAPhase 1Prostate Cancer (CRPC)Nov 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07214961AB001Phase 1Prostate Cancer (CRPC)OncologyNov 2027

Targets

PSMA (1)

Companies with the same targets

Clarity Pharmaceuticals C Ray Therapeutics Nova Therapeutics Eli Lilly Fusion Pharmaceuticals Lantheus Medical Imaging Sinotau Pharmaceutical Group Norroy Bioscience Inovio Pharmaceuticals Curium US

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.